Robert  Janssen net worth and biography

Robert Janssen Biography and Net Worth

Dr. Janssen was appointed Chief Medical Officer and Vice President, Clinical Development in July 2013. He previously served as Dynavax's Vice President, Medical Affairs and Senior Director, Clinical Development. Prior to joining Dynavax in 2010, Dr. Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV. Dr. Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology at the University of Pennsylvania. Dr. Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific journals.

What is Robert Janssen's net worth?

The estimated net worth of Robert Janssen is at least $635,046.00 as of January 4th, 2024. Dr. Janssen owns 49,925 shares of Dynavax Technologies stock worth more than $635,046 as of December 22nd. This net worth approximation does not reflect any other investments that Dr. Janssen may own. Additionally, Dr. Janssen receives a salary of $861,520.00 as SVP at Dynavax Technologies. Learn More about Robert Janssen's net worth.

How old is Robert Janssen?

Dr. Janssen is currently 70 years old. There are 5 older executives and no younger executives at Dynavax Technologies. Learn More on Robert Janssen's age.

What is Robert Janssen's salary?

As the SVP of Dynavax Technologies Co., Dr. Janssen earns $861,520.00 per year. There are 2 executives that earn more than Dr. Janssen. The highest earning executive at Dynavax Technologies is Mr. Ryan Spencer, CEO & Director, who commands a salary of $1,490,000.00 per year. Learn More on Robert Janssen's salary.

How do I contact Robert Janssen?

The corporate mailing address for Dr. Janssen and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]. Learn More on Robert Janssen's contact information.

Has Robert Janssen been buying or selling shares of Dynavax Technologies?

Robert Janssen has not been actively trading shares of Dynavax Technologies during the last quarter. Most recently, Robert Janssen sold 1,500 shares of the business's stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $15.00, for a transaction totalling $22,500.00. Following the completion of the sale, the chief marketing officer now directly owns 49,925 shares of the company's stock, valued at $748,875. Learn More on Robert Janssen's trading history.

Who are Dynavax Technologies' active insiders?

Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.

Are insiders buying or selling shares of Dynavax Technologies?

In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 34,641 shares worth more than $457,999.23. The most recent insider tranaction occured on May, 31st when Director Francis Cano sold 3,615 shares worth more than $43,126.95. Insiders at Dynavax Technologies own 3.0% of the company. Learn More about insider trades at Dynavax Technologies.

Information on this page was last updated on 5/31/2024.

Robert Janssen Insider Trading History at Dynavax Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2024Sell1,500$15.00$22,500.0049,925View SEC Filing Icon  
10/10/2023Sell1,755$15.01$26,342.5549,925View SEC Filing Icon  
10/2/2023Sell5,015$15.03$75,375.4549,925View SEC Filing Icon  
8/23/2023Sell34,857$15.01$523,203.5749,925View SEC Filing Icon  
8/8/2023Sell2,600$15.05$39,130.0049,925View SEC Filing Icon  
8/9/2022Sell7,938$16.92$134,310.9635,519View SEC Filing Icon  
3/3/2022Sell24,036$10.57$254,060.52View SEC Filing Icon  
8/16/2021Sell2,917$12.36$36,054.128,276View SEC Filing Icon  
8/11/2021Sell49,583$12.06$597,970.9856,444View SEC Filing Icon  
8/6/2021Sell80,000$10.75$860,000.006,861View SEC Filing Icon  
7/17/2020Sell50,000$11.09$554,500.00127,266View SEC Filing Icon  
5/19/2020Sell15,000$6.33$94,950.00177,266View SEC Filing Icon  
5/5/2020Sell9,000$4.43$39,870.00220,266View SEC Filing Icon  
1/24/2017Buy6,000$4.04$24,240.0012,048View SEC Filing Icon  
6/28/2016Buy1,452$13.68$19,863.366,048View SEC Filing Icon  
5/12/2016Buy1,000$15.12$15,120.001,000View SEC Filing Icon  
See Full Table

Robert Janssen Buying and Selling Activity at Dynavax Technologies

This chart shows Robert Janssen's buying and selling at Dynavax Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dynavax Technologies Company Overview

Dynavax Technologies logo
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $12.72
Low: $12.68
High: $12.95

50 Day Range

MA: $12.24
Low: $10.46
High: $13.66

2 Week Range

Now: $12.72
Low: $9.74
High: $15.01

Volume

4,031,312 shs

Average Volume

2,119,194 shs

Market Capitalization

$1.67 billion

P/E Ratio

97.85

Dividend Yield

N/A

Beta

1.33